Wijnen, R.; Pecoraro, C.; Carbone, D.; Fiuji, H.; Avan, A.; Peters, G.J.; Giovannetti, E.; Diana, P.
Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers 2021, 13, 4389.
https://doi.org/10.3390/cancers13174389
AMA Style
Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters GJ, Giovannetti E, Diana P.
Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers. 2021; 13(17):4389.
https://doi.org/10.3390/cancers13174389
Chicago/Turabian Style
Wijnen, Rosa, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti, and Patrizia Diana.
2021. "Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC)" Cancers 13, no. 17: 4389.
https://doi.org/10.3390/cancers13174389
APA Style
Wijnen, R., Pecoraro, C., Carbone, D., Fiuji, H., Avan, A., Peters, G. J., Giovannetti, E., & Diana, P.
(2021). Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers, 13(17), 4389.
https://doi.org/10.3390/cancers13174389